March 19, 2019 The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients
March 18, 2019 Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson’s Disease Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, Ahamadi M, Cedarbaum J, Seibyl J, Marek K, Basseches P, Hill D...
March 18, 2019 C-Path President and CEO, Board Director Selected to Serve on Esteemed National Academies of Sciences, Engineering and Medicine Committee C-Path President and CEO Martha Brumfield, PhD, and C-Path Board Director Alastair J. Wood, MD, FRCP, have both been selected to t
March 17, 2019 Increasing Efficiency, Safety, and Speed in Clinical Trials for Neurodegenerative Diseases | Alzheimer’s Drug Discovery Foundation Conference, Long Beach, CA
March 14, 2019 C-Path, FNIH Announce Clinical Development User’s Guide for Kidney Safety Biomarkers TUCSON, Ariz., March 14, 2019 — The Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium (PST
March 10, 2019 Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth
February 27, 2019 C-Path and FARA Launch Friedreich’s Ataxia Integrated Clinical Database to Advance the Development of Treatments for FA TUCSON, Ariz. and DOWNINGTOWN, Penn., February 27, 2019 — Critical Path Institute’s (C-Path) Data Collaboration Center (DCC) a
February 23, 2019 Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies
February 19, 2019 Delving into the Role of Public Private Partnerships in Shaping the Landscape to Enable Precision Medicine for Neurodegeneration | 7th World CNS Summit, Boston, MA
